Dysphonia and airway obstruction are rarely caused by Kaposi's Sarcoma (KS). We present the case of a 40 year old man receiving his diagnosis of human immunodeficiency virus (HIV) after presenting with hoarseness caused by laryngeal KS. HIV may contribute to KS growth by stimulating excess production of angiogenic lymphokines and monokines and by decreasing immune surveillance. Histopathology reveals proliferating endothelial cells, fibroblasts, thin vascular slits, and extravasated erythrocytes. A wide variety of localized treatment options exist, while chemotherapeutic agents and alpha-interferon are used for multifocal or widespread disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvoice.2004.04.007 | DOI Listing |
J Virol
January 2025
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) is a human gammaherpesvirus associated with Kaposi's sarcoma and B cell malignancies. Like all herpesviruses, KSHV contains conserved envelope glycoproteins (gps) involved in virus binding, entry, assembly, and release from infected cells, which are also targets of the immune response. Due to the lack of a reproducible animal model of KSHV infection, the precise functions of the KSHV gps during infection are not completely known.
View Article and Find Full Text PDFJ Med Virol
January 2025
Department of Infection Biology, Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) employs diverse mechanisms to subvert host immune responses, contributing to its infection and pathogenicity. As an immune evasion strategy, KSHV encodes the Membrane-Associated RING-CH (MARCH)-family E3 ligases, K3, and K5, which target and remove several immune regulators from the cell surface. In this study, we investigate the impact of K3 and K5 on lymphotoxin receptor (LTβR) ligands, LTβ and LIGHT, which are type II transmembrane proteins and function as pivotal immune mediators during virus infection.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Dermatology, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA.
A woman in her 70s with well-controlled HIV on antiretroviral therapy presented with a several-month history of an asymptomatic perianal lesion. Skin examination showed a 0.5-1 cm red-pink, shiny, exophytic papule with visible telangiectasias near the anal verge.
View Article and Find Full Text PDFPhotodiagnosis Photodyn Ther
January 2025
Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
A 84-year old man who has a history of refractory Kaposi's sarcoma (KS) was treated with ALA-PDT combined with the dual 980-nm/1470-nm diode laser for 6 times every other week. Satisfactory result was noted without any unbearable adverse effects. The combination of the dual 980nm/1470nm diode laser and ALA-PDT may be an ideal strategy in treating local KS with good tolerance, especially in elder patients who can not tolerate radiotherapy and chemotherapy.
View Article and Find Full Text PDFPLoS Pathog
January 2025
Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
IKKε is a traditional antiviral kinase known for positively regulating the production of type I interferon (IFN) and the expression of IFN-stimulated genes (ISGs) during various virus infections. However, through an inhibitor screen targeting cellular kinases, we found that IKKε plays a crucial role in the lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV). Mechanistically, during KSHV lytic replication, IKKε undergoes significant SUMOylation at both Lys321 and Lys549 by the viral SUMO E3 ligase ORF45.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!